Skip to main content
. 2020 Sep 22;9(9):2143. doi: 10.3390/cells9092143

Figure 4.

Figure 4

NFs miR-9/siEFEMP1 reduce tumor cell sensitivity to cisplatin. MDA-MB-468 cell count upon treatment with cisplatin (24 h) after 24h of conditioning with the supernatant of (a) NFs miR-9 or (b) si-EFEMP1, compared to controls. Cell count data are presented as mean of the percentage of viable treated (CISP = cisplatin) cells of three biological replicates, compared to non-treated (NT) cells, ±SEM (** p < 0.01, *** p < 0.001).